Immunotherapy最新文献

{"title":"Immunotherapy-related secondary hemophagocytosis in a glioblastoma patient: response to cytokine-directed therapy.","authors":"Ozkan Alan, Mustafa Cem Bulbul, Mehmet Ali Enlice, Nil Molinas Mandel","doi":"10.1080/1750743X.2025.2451604","DOIUrl":"10.1080/1750743X.2025.2451604","url":null,"abstract":"<p><p>Hemophagocytic Lymphohistiocytosis (HLH) is a severe and potentially life-threatening condition characterized by an excessive and uncontrolled activation of the immune system. ICI-related hemophagocytic lymphohistiocytosis (irHLH) is a rare immune-related adverse event with an incidence of 0.03% to 0.4%. Although rare, it can be potentially lethal, with a high mortality rate of up to 50% in some cases. We present a patient with recurrent glioblastoma who developed Hemophagocytic Lymphohistiocytosis s a result of nivolumab treatment and was subsequently managed with cytokine-directed therapy (tocilizumab). Early diagnosis and treatment of Hemophagocytic Lymphohistiocytosis (HLH) associated with immune checkpoint inhibitors (ICIs) are indeed crucial due to the potentially life-threatening nature of the condition.Cytokine-based treatments (such as anti-IL-6) may be appropriate for patients who do not respond to high-dose steroids.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"11-17"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834416/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142983396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations.","authors":"Matilde Corianò, Alessandro Lazzarin, Michele Maffezzoli, Matteo Santoni, Giulia Mazzaschi, Sara Rodella, Nicola Simoni, Eleonora Lai, Marco Maruzzo, Umberto Basso, Davide Bimbatti, Roberto Iacovelli, Annunziato Anghelone, Ondřej Fiala, Sara Elena Rebuzzi, Giuseppe Fornarini, Cristian Lolli, Francesco Massari, Matteo Rosellini, Veronica Mollica, Cecilia Nasso, Alessandro Acunzo, Enrico Maria Silini, Federico Quaini, Massimo De Filippo, Matteo Brunelli, Giuseppe L Banna, Pasquale Rescigno, Alessio Signori, Sebastiano Buti","doi":"10.1080/1750743X.2025.2452145","DOIUrl":"10.1080/1750743X.2025.2452145","url":null,"abstract":"<p><strong>Background: </strong>The present study aimed to investigate the prognostic and predictive roles of Hb/RDW ratio in patients with mRCC treated with first-line immunotherapy combinations (TKI plus ICI or ICI plus ICI).</p><p><strong>Materials and methods: </strong>We performed a sub-analysis of a multicenter retrospective observational study (ARON-1 project) involving patients with mRCC treated with first-line immunotherapy combinations.</p><p><strong>Results: </strong>Three hundred and twenty-nine patients were enrolled, 244 males and 85 females. Median age was 65.5 years. The prognostic impact of the Hb/RDW ratio on PFS and OS was observed in the whole population examined. Hb/RDW ratio had a correlation with neutrophil-to-lymphocyte ratio (NLR), a blood inflammatory parameter.</p><p><strong>Conclusion: </strong>Hb/RDW ratio is a new inflammatory prognostic factor, easy to use in daily clinical practice.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"25-35"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143004827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anakinra in relapsing polychondritis: a case report and review of the literature.","authors":"Syed B Ali, Tiffany Hughes, Anthony Smith","doi":"10.1080/1750743X.2024.2443381","DOIUrl":"10.1080/1750743X.2024.2443381","url":null,"abstract":"<p><p>Relapsing polychondritis is rare and affects non-synovial fibrocartilage. Currently, there is a paucity of treatment algorithms, especially for those with refractory disease. A middle-aged man presented with polychondritis affecting the nose, ears, joints, and larynx. Two months prior, a diagnosis of non-arteritic ischemic optic neuropathy was made. Oral prednisolone was initiated, and over the following three years, he had several flares for which the following other treatments were given: moderate dose methotrexate (elevated liver enzymes), azathioprine (gastrointestinal intolerance), mycophenolate (ineffective), tocilizumab (widespread eruption), and tofacitinib (acute diverticulitis). Further investigations were unremarkable for malignancy and vasculitis. UBA1 mutation screening was negative. Given the limited therapeutic options, methotrexate at a lower dose was re-added, but he developed acute flare with laryngeal symptoms. Anakinra was initiated, prompting a successful prednisolone wean over the following weeks and disease remission. A literature review identified 11 publications comprising 25 patients. Of the 21 patients with anakinra response documented, six (28.6%) had symptomatic improvement. In one of these patients, there was co-administration of methotrexate. In summary, anakinra may remain as an option, only for those subsets of patients in whom many of the other more efficacious treatments have been tried to provide sustained disease control.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"5-9"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834529/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142864162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune checkpoint inhibitors in gynecological cancers: a narrative review on the practice-changing trials.","authors":"Cecilia Nasso, Silvia Puglisi, Sara Elena Rebuzzi, Veronica Errigo, Francesca Rosa, Ilaria Chiola, Caterina Lazzari, Yuri Musizzano, Ezio Venturino, Alessandro Gastaldo, Caterina Siccardi, Eugenio Oreste Volpi, Serafina Mammoliti, Marco Benasso","doi":"10.1080/1750743X.2025.2460964","DOIUrl":"10.1080/1750743X.2025.2460964","url":null,"abstract":"<p><p>During the last decades, the introduction of immune checkpoint inhibitors has radically changed the treatment landscape of several cancer types, improving the prognosis and the quality of life of cancer patients. Even for gynecological cancers, where the prognosis has historically been poor despite advancements in surgery, radiotherapy and oncological treatment, immunotherapy has represented a significant leap forward. In cervical and endometrial cancer, the introduction of immunotherapy has radically changed the treatment algorithm, especially for advanced disease. However, the scenario remains less promising for ovarian cancer, where, despite extensive research efforts, no consistent positive results have been achieved with immune checkpoint inhibitors, except for a few cases in rarer histological subtypes Here, we present a narrative review summarizing the most important practice-changing studies involving immune checkpoint inhibitors in gynecological cancers, particularly in cervical, endometrial, ovarian and vulvar cancer.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"57-66"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834418/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143074300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How could histotripsy change cancer immunotherapy?","authors":"Heineken Queen, Clifford S Cho","doi":"10.1080/1750743X.2024.2442899","DOIUrl":"10.1080/1750743X.2024.2442899","url":null,"abstract":"","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-3"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834414/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142846600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of benralizumab in patients with severe eosinophilic asthma (SEA): A plain language summary of the ANANKE study.","authors":"G W Canonica,L Consani,L Malerba,G Pelaia,A Vultaggio,","doi":"10.1080/1750743x.2024.2386899","DOIUrl":"https://doi.org/10.1080/1750743x.2024.2386899","url":null,"abstract":"WHAT IS THIS SUMMARY ABOUT?This summary outlines the findings from the ANANKE study on the treatment of patients with severe eosinophilic asthma (SEA) with benralizumab. SEA is an inflammatory disease of the lungs caused by eosinophils. Patients with SEA may experience asthma attacks (exacerbations) and decreased ability to breathe (lung function) despite taking medications. Benralizumab (Fasenra®) is a biologic therapy (a medicine produced using living cells) approved for the treatment of SEA.The ANANKE study was conducted in Italy and evaluated the characteristics of patients with SEA who received benralizumab as prescribed by their doctors. It also described the effects of benralizumab on participants in terms of frequency of exacerbations, lung function and overall control of asthma, and their need to take oral corticosteroids (OCS) to control symptoms. The effects of benralizumab have been observed in participants treated for: 1) an average of 10.3 months, and 2) up to 96 weeks (approximately 2 years). The effects were also compared between different groups: 1) participants with chronic rhinosinusitis with nasal polyps (CRSwNP) and those without, and 2) participants who received other biologics before benralizumab (bio-experienced) and those who started with benralizumab as their first biologic (naïve). CRSwNP is an inflammatory condition that makes breathing even more difficult.WHAT WERE THE KEY FINDINGS?Before receiving benralizumab, participants showed a high blood eosinophil count (the number of eosinophils in the bloodstream), frequent exacerbations, insufficient lung function, and poor disease control (symptom management). After 96 weeks, benralizumab almost eliminated exacerbations, improved lung function, reduced the use of OCS, and increased the control of SEA symptoms while lowering blood eosinophil count. Comparable effects were observed between participants with and without CRSwNP and between naïve and bio-experienced participants.WHAT WERE THE MAIN CONCLUSIONS REPORTED BY THE RESEARCHERS?The ANANKE study showed that participants had frequent exacerbations and were characterized by eosinophilic inflammation before starting benralizumab. Overall, benralizumab improved the control of the disease for up to 2 years and induced similar beneficial effects regardless of the presence of CRSwNP and the use of previous biologics. These findings highlight the long-lasting and broad action of benralizumab.Clinical Trial Registration: NCT04272463 (ANANKE) (ClinicalTrials.gov).","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":"6 1","pages":"1-11"},"PeriodicalIF":2.8,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142247536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between toxicity and efficacy of immune checkpoint inhibitors in older adults with NSCLC.","authors":"Yiran Rong,Sujith Ramachandran,Kaustuv Bhattacharya,Yi Yang,Sally Earl,Yunhee Chang,John P Bentley","doi":"10.1080/1750743x.2024.2394382","DOIUrl":"https://doi.org/10.1080/1750743x.2024.2394382","url":null,"abstract":"Aim: This cohort study evaluated the association between immune checkpoint inhibitors (ICIs)-induced immune-related adverse events (irAEs) and mortality as well as ICI discontinuation among older adults with NSCLC.Methods: 2007-2019 Surveillance, Epidemiology and End Results-Medicare linked database was used and survival analysis with time-varying exposure of irAEs was applied to estimate the associations.Results & conclusion: A total of 8,175 individuals were included, with 46.8% of whom developed an irAE. Cox regression models showed the occurrence of any irAEs was associated with increased risk of mortality (HR: 1.73, 95% CI: 1.63-1.82) and treatment discontinuation (HR: 1.87, 95% CI: 1.78-1.97). Some variability was observed in the effect on the two outcomes depending on the type of irAE.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":"196 1","pages":"1-12"},"PeriodicalIF":2.8,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142247539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Symptomatic aseptic sinusitis induced by immune checkpoint inhibitors for metastatic melanoma treatment.","authors":"Sofia Tzoumpa,Béatrice Villette,Florence Granel-Brocard,Caroline Dutriaux,Alexandre Memmi,Geraldine Jeudy,Victor Tafani,Melanie Saint-Jean,Charlee Nardin,Elisa Funck-Brentan,Yannick Le Corre,Gaëlle Quereux,Eve Maubec","doi":"10.1080/1750743x.2024.2399498","DOIUrl":"https://doi.org/10.1080/1750743x.2024.2399498","url":null,"abstract":"Immune-mediated sinusitis is poorly described and may easily go undiagnosed. We conducted a retrospective, multicenter, national study focusing on symptomatic immune-mediated sinusitis in patients receiving immune checkpoint inhibitors (ICIs) for melanoma treatment. Twelve patients were included (50% women, median age 58 years). Overall, the paraclinical assessment, the inefficacy of antibiotic/antihistaminic treatment, the improvement of symptoms on immunosuppressants and/or after ICI discontinuation, and the presence of multiple concomitant immune-related adverse-events, suggested a noninfectious etiology. Recognizing this toxicity is imperative for limitation of diagnostic wandering and appropriate treatment. However, additional epidemiological studies are needed to assess its prevalence as a potential immune-related adverse-event, and its prognostic value in patients treated with ICIs.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":"14 1","pages":"1-9"},"PeriodicalIF":2.8,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142247524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combining immunotherapy with PARP inhibitors. Is it possible to find the way through?","authors":"Georgios I Papageorgiou,Nikolaos Skouteris,Kleopatra Eleftheriou,Christos Kosmas","doi":"10.1080/1750743x.2024.2398412","DOIUrl":"https://doi.org/10.1080/1750743x.2024.2398412","url":null,"abstract":"","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":"8 1","pages":"1-5"},"PeriodicalIF":2.8,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142247523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors.","authors":"Ben Tran,Mark Voskoboynik,Johanna Bendell,Martin Gutierrez,Charlotte Lemech,Daphne Day,Sophia Frentzas,Ignacio Garrido-Laguna,Nathan Standifer,Fujun Wang,Charles Ferte,Yue Wang,Mayukh Das,Benedito A Carneiro","doi":"10.1080/1750743x.2024.2359359","DOIUrl":"https://doi.org/10.1080/1750743x.2024.2359359","url":null,"abstract":"Aim: This first-in-human study evaluated safety and efficacy of CD40 agonist MEDI5083 with durvalumab in patients with advanced solid tumors.Methods: Patients received MEDI5083 (3-7.5 mg subcutaneously every 2 weeks × 4 doses) and durvalumab (1500 mg every 4 weeks) either sequentially (N = 29) or concurrently (N = 9). Primary end point was safety; secondary end points included efficacy.Results: Thirty-eight patients received treatment. Most common adverse events (AEs) were injection-site reaction (ISR; sequential: 86%; concurrent: 100%), fatigue (41%; 33%), nausea (20.7%; 55.6%) and decreased appetite (24.1%; 33.3%). Nine patients had MEDI5083-related grade ≥3 AEs with ISR being the most common. Two patients experienced dose limiting toxicities (ISR). One death occurred due to a MEDI5083-related AE. MEDI5083 maximum tolerated dose was 5 mg. Objective response rate was 2.8% (1 partial response and 11 stable disease).Conclusion: MEDI5083 toxicity profile limits its further development.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":"38 1","pages":"1-16"},"PeriodicalIF":2.8,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142247537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}